WO2009148245A3 - Novel niacin and hmg-coa reductase inhibitor combination formulation - Google Patents

Novel niacin and hmg-coa reductase inhibitor combination formulation Download PDF

Info

Publication number
WO2009148245A3
WO2009148245A3 PCT/KR2009/002923 KR2009002923W WO2009148245A3 WO 2009148245 A3 WO2009148245 A3 WO 2009148245A3 KR 2009002923 W KR2009002923 W KR 2009002923W WO 2009148245 A3 WO2009148245 A3 WO 2009148245A3
Authority
WO
WIPO (PCT)
Prior art keywords
niacin
hmg
formulation
coa reductase
reductase inhibitor
Prior art date
Application number
PCT/KR2009/002923
Other languages
French (fr)
Korean (ko)
Other versions
WO2009148245A2 (en
WO2009148245A4 (en
Inventor
최연웅
민병구
조상민
김종일
김대욱
정용미
장재상
류병환
Original Assignee
주식회사 서울제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 서울제약 filed Critical 주식회사 서울제약
Publication of WO2009148245A2 publication Critical patent/WO2009148245A2/en
Publication of WO2009148245A3 publication Critical patent/WO2009148245A3/en
Publication of WO2009148245A4 publication Critical patent/WO2009148245A4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention relates to a controlled release formulation containing niacin. More specifically, the present invention relates to a controlled release-niacin formulation and a preparation method thereof, wherein the controlled release-niacin formulation comprises niacin, hydroxypropyl methylcellulose, carboxyvinyl polymers, additives, disintegrants, and lubricants, wherein the carboxyvinyl polymer and hydroxypropyl methylcellulose are included so that the weight ratio of the carboxyvinyl polymer: HPMC is 1:1 – 1:100. In addition, the present invention provides a combination formulation further containing an HMG-CoA reductase inhibitor in the controlled release-niacin formulation and a preparation method thereof.
PCT/KR2009/002923 2008-06-02 2009-06-02 Novel niacin and hmg-coa reductase inhibitor combination formulation WO2009148245A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080051873A KR20090125660A (en) 2008-06-02 2008-06-02 Hmg-coa reductase inhibitor combination formulation
KR10-2008-0051873 2008-06-02

Publications (3)

Publication Number Publication Date
WO2009148245A2 WO2009148245A2 (en) 2009-12-10
WO2009148245A3 true WO2009148245A3 (en) 2010-03-04
WO2009148245A4 WO2009148245A4 (en) 2010-04-22

Family

ID=41398656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002923 WO2009148245A2 (en) 2008-06-02 2009-06-02 Novel niacin and hmg-coa reductase inhibitor combination formulation

Country Status (2)

Country Link
KR (1) KR20090125660A (en)
WO (1) WO2009148245A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022508A (en) * 1997-07-31 2001-03-15 추후보정 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT
US6893661B1 (en) * 1997-04-21 2005-05-17 Biovail Corporation Controlled release formulations using intelligent polymers
KR20050110444A (en) * 2004-05-19 2005-11-23 주식회사 서울제약 Controlled release oral dose forms containing niacin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6893661B1 (en) * 1997-04-21 2005-05-17 Biovail Corporation Controlled release formulations using intelligent polymers
KR20010022508A (en) * 1997-07-31 2001-03-15 추후보정 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT
KR20050110444A (en) * 2004-05-19 2005-11-23 주식회사 서울제약 Controlled release oral dose forms containing niacin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JAMZAD, S. ET AL.: "Development of a controlled release low dose class II drug- Glipizide", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 312, 2006, pages 24 - 32 *

Also Published As

Publication number Publication date
WO2009148245A2 (en) 2009-12-10
WO2009148245A4 (en) 2010-04-22
KR20090125660A (en) 2009-12-07

Similar Documents

Publication Publication Date Title
WO2009156462A3 (en) Organic compounds
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
WO2011109563A3 (en) Ethylene-based polymer compositions
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
WO2011002868A3 (en) Ethylene-based polymer compositions
MY150542A (en) Cmet inhibitors
WO2009087098A3 (en) Quinoline derivatives and their use as fungicides
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2010008847A3 (en) Pi3k/m tor inhibitors
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
MX341825B (en) Heteroaryl compounds and uses thereof.
WO2006007532A3 (en) 2-substituted heteroaryl compounds
MX2010003155A (en) Cyclopropyl aryl amide derivatives and uses thereof.
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
AU2009215534A8 (en) Compounds that are ERK inhibitors
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
WO2011031896A3 (en) Pi3 kinase inhibitors and uses thereof
WO2011073341A3 (en) Polymer dispersions
JO2985B1 (en) MAPK/ERK Kinase Inhibitors
WO2009042114A3 (en) Phenazine derivatives and uses thereof
MY161461A (en) Akt and p70 s6 kinase inhibitors
WO2011106248A3 (en) Trimethoxyphenyl inhibitors of tyrosine kinase
WO2012041837A3 (en) Method for producing higher hydridosilane compounds
CA2562418A1 (en) Sustained release formulation for oral administration of hmg-coa reductase inhibitor and method for the preparation thereof
WO2005014539A3 (en) Pyrrole-based hmg-coa reductase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09758498

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09758498

Country of ref document: EP

Kind code of ref document: A2